Mail slow? View this month’s issue, right online!
Our digital version is easy to share with colleagues. See this month’s issue and digital versions of previous issues too.
Get your products and services in front of thousands of decision-makers. View our print and online advertising options.
A one-on-one interview conducted by our editorial team with industry leaders in our market.
Discover the newest promotions and collaborations within the industry.
Easy-to-digest data for your business.
Shampoos, conditioners, colorants and styling products created by leading industry suppliers.
Creams, serums, facial cleansers and more created by leading suppliers to the skincare industry.
Detergents, fabric softeners and more created by leading suppliers to the fabric care industry.
Eyeshadows, lipsticks, foundations and more created by leading suppliers to the color cosmetics industry.
Bodywashes, and bar and liquid soaps created by leading suppliers to the personal cleanser industry.
Hard surface cleaners, disinfectants and more created by leading suppliers to the home care industry.
Eau de parfums and eau de toilettes, body sprays, mists and more created by leading suppliers to the fragrance industry.
UV lotions and creams, self-tanners and after-sun products created by leading suppliers to the suncare industry.
A detailed look at the leading US players in the global household and personal products industry.
A detailed look at the leading players outside the US in the global household and personal products industry.
Looking for a new raw material or packaging component supplier? Your search starts here.
When you need a new manufacturing partner or private label company, get started here.
Who owns that? To keep track of leading brands and their owners, click here.
An annual publication, Company Profiles features leading industry suppliers with information about markets served, products, technologies and services for beauty, pesonal care and home care.
New products and technologies from some of the brightest minds in the industry.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to the leading experts in the global household and personal products industry.
Comprehensive coverage of key topics selected by sponsors.
Detailed research on novel ingredients and other solutions for the global household and personal care industry.
Company experts explain what works and why.
Exclusive content created by our affiliates and partners for the household and personal care industry.
Exciting news releases from the household and personal care industry.
Our targeted webinars provide relevant market information in an interactive format to audiences around the globe.
Discover exclusive live streams and updates from the hottest events and shows.
Looking for a job in the household and personal care industry, search no further.
Follow these steps to get your article published in print or online
What are you searching for?
Proteologix has bispecific antibodies ready to enter phase 1 and in preclinical development for moderate to severe AD.
May 17, 2024
By: Christine Esposito
Editor-in-Chief
Johnson & Johnson may have spun off its consumer skin health unit—now known as Kenvue—in 2023, but finding new treatments for challenging skin conditions remains a focus for the healthcare giant. The company is acquiring Proteologix, a privately-held biotech company focused on bispecific antibodies for treatment of severe atopic dermatitis (AD) and other auto immune diseases. Proteologix’s portfolio includes PX128, a bispecific antibody ready to enter phase 1 development for moderate to severe AD and moderate to severe asthma, and PX130, a bispecific antibody in preclinical development for moderate to severe AD. “Atopic dermatitis is the most common inflammatory skin disease, impacting more than 100 million adults worldwide,” said David Lee, global immunology therapeutic area head, Johnson & Johnson Innovative Medicine. “About 70% of patients using existing standard of care therapies do not reach remission1. Current advanced therapies for AD either target a single pathway and have limited efficacy or are more broadly immunosuppressive, resulting in significant safety concerns. We see an opportunity for best-in-disease efficacy for both PX128 and PX130 as each bispecific antibody targets two different combinations of disease driving pathways that are mediating the skin inflammation in heterogenous subpopulations of AD patients.” Johnson & Johnson spun off its consumer skin health unit, now known as Kenvue, in 2023. Proteologix’s PX128 inhibits IL-13-mediated Th2 skin inflammation, an important disease-driving pathway in AD and asthma, as well as TSLP, a mediator of tissue inflammation in AD and asthma. Like PX128, PX130 inhibits IL-13-mediated Th2 skin inflammation. PX130 also inhibits IL-22 to restore the skin barrier and prevent inflammation from environmental triggers, such as allergens. Both assets are designed for infrequent dosing intervals, which offers convenience patients prefer. Together, these pipeline additions demonstrate a strategic approach to build a portfolio of differentiated and complementary bispecifics, according to J&J. Johnson & Johnson will acquire Proteologix’ for $850 million in cash, with potential for an additional milestone payment.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !
